Lecanemab Gains FDA Approval for Early Alzheimer Disease

JAMA. 2023 Feb 7;329(5):363. doi: 10.1001/jama.2022.24490.
No abstract available

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Drug Approval*
  • Humans
  • United States
  • United States Food and Drug Administration

Substances

  • lecanemab
  • Antibodies, Monoclonal, Humanized